一名同时表达p190（BCR-ABL）癌蛋白和JAK2V617F突变的慢性髓性白血病患者对伊马替尼的反应 - Suppr

Suppr

超能文献

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.

作者信息

Caocci G, Atzeni S, Orrù N, Littera R, Culurgioni F, Marongiu F, La Nasa G

出版信息

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.

DOI:10.1016/j.leukres.2009.08.009

PMID:19748671

Abstract

摘要

相似文献

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.一名同时表达p190（BCR-ABL）癌蛋白和JAK2V617F突变的慢性髓性白血病患者对伊马替尼的反应

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.

Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.伴有e13a3 BCR-ABL融合的慢性髓性白血病：对伊马替尼反应良好的良性病程及逆转录聚合酶链反应建议

Am J Hematol. 2004 Feb;75(2):92-5. doi: 10.1002/ajh.10456.

Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.

Pediatr Blood Cancer. 2008 May;50(5):1078. doi: 10.1002/pbc.21439.

E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.E355G 突变出现在一名对伊马替尼耐药的 e19a2 慢性髓性白血病患者中。

J Clin Pathol. 2010 Aug;63(8):737-40. doi: 10.1136/jcp.2010.078311.

Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.

Leuk Res. 2009 Jun;33(6):e10-2. doi: 10.1016/j.leukres.2008.10.028. Epub 2008 Dec 17.

Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.

Ann Hematol. 2003 Jun;82(6):333-5. doi: 10.1007/s00277-003-0660-y. Epub 2003 May 7.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.并非所有慢性粒细胞白血病中的伊马替尼耐药都是由BCR-ABL激酶结构域突变引起的。

Ann Hematol. 2006 Dec;85(12):841-7. doi: 10.1007/s00277-006-0171-8. Epub 2006 Sep 28.

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].[采用实时定量逆转录聚合酶链反应监测甲磺酸伊马替尼治疗的慢性髓性白血病患者的bcr/abl mRNA水平]

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5.

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.JAK2-V617F突变与费城染色体阳性慢性髓性白血病

Leuk Res. 2009 Nov;33(11):e212-3. doi: 10.1016/j.leukres.2009.06.011. Epub 2009 Jul 9.

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].[通过实时定量逆转录聚合酶链反应检测和定量慢性髓性白血病患者的BCR-ABL转录本]

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):453-7.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.同时存在JAK2 V617F和BCR::ABL1的患者的临床、形态学和遗传学特征

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.慢性骨髓增殖性肿瘤中突变与易位的同时出现：一种潜在的混淆性基因组合。

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.并发JAK2阳性骨髓增殖性疾病和慢性粒细胞白血病：一种新的实体？一例病例报告并文献复习

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.伴有 BCR-ABL1 易位和 JAK2 V617F 突变的骨髓增殖性肿瘤：来自骨髓病理学组的多机构研究。

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.一名患有原发性血小板增多症的孕妇中JAK2V617F突变与BCR-ABL易位并存。

Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):331-4. doi: 10.1007/s12288-014-0385-1. Epub 2014 Apr 11.

Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.慢性髓性白血病患者同时存在 BCR-ABL 融合和 JAK2 V617F 突变。

Int J Hematol. 2014 Jan;99(1):87-90. doi: 10.1007/s12185-013-1480-z. Epub 2013 Nov 30.

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.两名 CML 患者在接受甲磺酸伊马替尼治疗后完全细胞遗传学缓解时，随后出现了 JAK2-V617F 突变的特发性血小板增多症特征。

Int J Hematol. 2013 Jun;97(6):804-7. doi: 10.1007/s12185-013-1326-8. Epub 2013 Apr 24.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验